Conference Coverage

Visual snow: Alarming and not uncommon


 

FROM 2021 SCOTTSDALE HEADACHE SYMPOSIUM

Limited treatment options

Unfortunately, there is little evidence on medications to treat the problem. According to Dr. Robertson, the best available evidence – from case reports – is for lamotrigine. Nearly 20% of patients achieve a partial response, and complete responses are rare.

Clinical trials are a possibility, but patients should be made aware that medications have the potential to worsen visual snow.

Nonpharmaceutical approaches include visual and mental distraction, along with manipulation of lighting at work and at home. Stress reduction may help, and Dr. Robertson may send patients with dizziness for visual vestibular therapy to work on visual motion desensitization exercises.

There are visual snow relief videos available on YouTube, which may provide temporary relief. “It’s probably similar to white noise therapy for tinnitus,” said Dr. Robertson.

Colored glass lenses may be helpful. “I’m having the best success at this point with FL-41 lenses. Some prefer amber, and others prefer the rose-tinted, just like migraine. I usually start with that,” said Dr. Robertson. Yellow lenses may help with nyctalopia.

She recommends that patients avoid consuming too much caffeine, and that they avoid stimulants, especially attention-deficit disorder (ADD) medications. “I’ve had a lot of patients worsen with ADD medication,” said Dr. Robertson. She also warns patients away from marijuana and hallucinogens.

There is a large community available for patients with visual snow, including more than 60 Facebook groups, and many YouTube videos of patients describing their experiences. There is even a visual snow simulator that neurologists can show patients to confirm what they are seeing. “It’s very validating for the patient,” said Dr. Robertson.

Dr. Charles noted the relatively few treatment options and poor understanding of the mechanisms behind the condition. “It’s incredibly frustrating that we have to tell them that we have so little understanding of basic mechanisms, and no really clear therapeutic strategy that we can apply across all patients and expect results,” said Dr. Charles.

The heightened interest in the condition does represent some hope. “It’s very much reassuring to people that, number one, we’re starting to understand it – but number two, that they’re not crazy. It’s very much validating to hear that it’s now a topic of much more rigorous investigation,” said Dr. Charles.

Dr. Robertson and Dr. Charles have no relevant financial disclosures.

Pages

Recommended Reading

Assessing headache severity via migraine symptoms can help predict outcomes
MDedge Neurology
FDA okays new oral CGRP antagonist for migraine prevention
MDedge Neurology
Migraine history linked to more severe hot flashes in postmenopausal women
MDedge Neurology
Pandemic survey: Forty-six percent of pediatric headache patients got worse
MDedge Neurology
New antimigraine drugs linked with less risk for adverse events
MDedge Neurology
DIY nerve stimulation effective in episodic migraine
MDedge Neurology
Patients given NSAIDs over antiemetics for headaches spend less time in the ED
MDedge Neurology
Largest ever review of new daily persistent headache assesses its clinical features
MDedge Neurology
Erenumab beats topiramate for migraine in first head-to-head trial
MDedge Neurology
Headache is a common post–COVID-19 complaint
MDedge Neurology